PET scans with the radiotracer F-18 fluorothymidine (FLT) can help determine which glioblastoma patients have the best chance for longer survival, according to a study published online on July 21 in the European Journal of Nuclear Medicine and Molecular Imaging. {read more here}

The treatment was administered at different dosing levels. After 18 months, those receiving the highest dose had an 81 percent reduction in amyloid buildup as measured in PET scans and a 30 percent reduction in clinical indicators of early Alzheimer’s. {read more here}

Positron emission tomography (PET)-based imaging may offer a promising alternative to conventional imaging for characterizing the true extent of disease in men who experience early biochemical recurrence following primary treatment for prostate cancer (PCa), according to a new systematic review and meta-analysis published in the World Journal of Urology. {read more here}

The small study involved seven military personnel — five veterans and two active duty — who’d had brain injuries and experienced CTE-type symptoms, such as memory loss and mood swings. They were injected with FDDNP. The FDDNP tracer binds with the abnormal proteins in the brain and then appears in neural PET scans. {read more here}